- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01103089
Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)
October 11, 2011 updated by: AstraZeneca
The purpose of the study is to determine patient characteristics from patients that have used Iressa for a period of minimal 3 years.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
10
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Amsterdam, Netherlands
- Research Site
-
Apeldoorn, Netherlands
- Research Site
-
Den Haag, Netherlands
- Research Site
-
Groningen, Netherlands
- Research Site
-
Helmond, Netherlands
- Research Site
-
Hengelo, Netherlands
- Research Site
-
Hoofddorp, Netherlands
- Research Site
-
Leiden, Netherlands
- Research Site
-
Veldhoven, Netherlands
- Research Site
-
Venlo, Netherlands
- Research Site
-
Zutphen, Netherlands
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients from the gefitinib Expanded Access Programme in the Netherlands.
Description
Inclusion Criteria:
- Participation in the gefitinib Expanded Access Program
- Patient still uses gefitinib in September 2009
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The following characteristics of the 'long-term responders' from the EAP; gender, ethnicity, smoking history (pack years), EGFR-TK mutation and histology of NSCLC.
Time Frame: Characteristics will be recorded once, retrospectively
|
Characteristics will be recorded once, retrospectively
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To assess the long-term safety in subjects treated with gefitinib by collecting information on: All adverse events that have lead to an interruption/reduction of gefitinib or another intervention
Time Frame: Once, retrospectively for the period the patient has used gefitinib (minimal 3 years)
|
Once, retrospectively for the period the patient has used gefitinib (minimal 3 years)
|
|
long-term safety in subjects; what real life data measures are being taken by lung physicians to counter side effects caused by long term gefitinib treatment; the number, reason, effect and description of interventions that have been taken
Time Frame: Once, retrospectively for the period the patient has used gefitinib (minimal 3 years)
|
Once, retrospectively for the period the patient has used gefitinib (minimal 3 years)
|
|
long-term safety: Number, reason and effect of interruptions during gefitinib use to determine side effects typical for the long-term treatment with gefitinib
Time Frame: Once, retrospectively for the period the patient has used gefitinib (minimal 3 years)
|
Once, retrospectively for the period the patient has used gefitinib (minimal 3 years)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2010
Primary Completion (Actual)
December 1, 2010
Study Completion (Actual)
December 1, 2010
Study Registration Dates
First Submitted
April 5, 2010
First Submitted That Met QC Criteria
April 13, 2010
First Posted (Estimate)
April 14, 2010
Study Record Updates
Last Update Posted (Estimate)
October 12, 2011
Last Update Submitted That Met QC Criteria
October 11, 2011
Last Verified
October 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NIS-ONL-IRE-2009/1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.